Patents by Inventor Edward John Yurkow

Edward John Yurkow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of mitigating toxic effects of vesicants and caustic gas
    Patent number: 11273203
    Abstract: Methods and kits for mitigating a toxic effect of at least one of vesicants and caustic gases in a subject in need thereof are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the toxic effect of the vesicant or caustic gas.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: March 15, 2022
    Assignees: Janssen Pharmaceutica NV, Rutgers, The State University of New Jersey
    Inventors: Gary Eichenbaum, Edward John Yurkow
  • METHODS OF MITIGATING TOXIC EFFECTS OF VESICANTS AND CAUSTIC GAS
    Publication number: 20200237870
    Abstract: Methods and kits for mitigating a toxic effect of at least one of vesicants and caustic gases in a subject in need thereof are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic, such as RWJ-800088 or romiplostim, is used to mitigate the toxic effect of the vesicant or caustic gas.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 30, 2020
    Inventors: Gary EICHENBAUM, Edward John YURKOW
  • Peptides and compounds that bind to a receptor
    Patent number: 7723295
    Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.
    Type: Grant
    Filed: August 9, 2005
    Date of Patent: May 25, 2010
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Brian R. MacDonald, Jeffery Kenneth Weis, Edward John Yurkow
  • Peptides and compounds that bind to a receptor
    Patent number: 7576056
    Abstract: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: August 18, 2009
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Brian R. MacDonald, Jeffery Kenneth Weis, Edward John Yurkow